Filippo Pigazzani

Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic

Yuri Bruinen de Bruin, Anne‐Sophie Lequarré, Josephine McCourt et al. · Safety Science · 2020 · 377 citations · Full text

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Isla S. Mackenzie, Ian Ford, George Nuki et al. · The Lancet · 2020 · 322 citations · Full text

Cardiovascular Disease, Gouty Arthritis, Pharmacotherapy +5

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial

Isla S. Mackenzie, Amy Rogers, Neil R Poulter et al. · The Lancet · 2022 · 203 citations · Full text

Blood Pressure Monitoring, Hypertension, Health Policy +10

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes

Francesca M. Notarangelo, Giuseppe Maglietta, P Bevilacqua et al. · Journal of the American College of Cardiology · 2018 · 188 citations · Full text

Thrombosis, Cardiovascular Disease, Blood Platelet +13

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Isla S. Mackenzie, Christopher J. Hawkey, Ian Ford et al. · The Lancet · 2022 · 143 citations · Full text